Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baloxavir Marboxil vs Oseltamivir in Chinese Pediatric Patients With Influenza
NCT06774859Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of baloxavir marboxil in influenza (2 arms), sponsored by Roche. Primary endpoint: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs). Started Oct 2024; status: completed.
02
Drugs
baloxavir marboxil
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06774859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06774859.